Navigation Links
Research Suggests FORTEO® Significantly Increases Bone Strength
Date:9/19/2011

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO® (teriparatide [rDNA origin] injection) on vertebral and proximal femoral strength, and the relationship of these effects to changes in the underlying volumetric BMD (vBMD) of postmenopausal women with osteoporosis. Researchers concluded that FORTEO increased vertebral and femoral strength in the spine and hip bones compared to baseline.1 These findings were presented in an oral presentation at the 2011 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego, Calif.

"Low bone strength is an important factor in the risk of fracture for patients with osteoporosis," said Tony Keaveny, MD, director, Orthopaedic Biomechanics Laboratory, Department of Mechanical Engineering, University of California, Berkeley. "These data provide supportive evidence that treatment with FORTEO has the potential to increase bone strength in two areas prone to fracture, the hip and spine."

The study used finite element analysis (FEA) of quantitative CT scans to measure changes in vertebral and proximal femoral strength. Although FEA is one of the most widely accepted means of non-invasive bone strength assessments, data are scarce on changes in vertebral and femoral bone strength for patients treated with FORTEO; therefore, the biomechanical effects of FORTEO treatment in postmenopausal women are not well understood.2

Researchers performed FEA of quantitative CT scans from study participants to measure bone strength and found statistically significant increases in both vertebral and femoral strength in women treated with FORTEO, compared to baseline (median: 16.6 percent and 2.3 percent, respectively, p≤0.05).3 The results indicated
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law ... William Scott has been nominated by his peers to earn a “Leading Lawyers” distinction. ... percent of attorneys in the state of Illinois. The nomination process is based on ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... fitness classes. , Starting September 1st they are offering pre and ... Bod" and "Healthy Body, Healthy Baby." , More information can be found at ...
(Date:8/31/2015)... ... , ... Coast Dental Vista is celebrating its recent grand opening ... p.m. near Albertsons in the Foothill Center, located at 1279 E. Vista Way. There ... Jay Lopp. Call (760) 208-2518 for more details or stop by on September 5. ...
(Date:8/31/2015)... ... ... In an article published August 24th on Healio, the author ... discusses the future of 3-D printing technology as it relates to the field of ... other 3-D printed tools could be used to aid in the treatment of patients ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... Program at Monmouth, was one of the first doctors in the area to ... this new approach have been impressive: faster recovery, decreased immediate and long-term pain, ...
Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4
... sick children, study finds , , TUESDAY, Nov. 20 (HealthDay ... at a children,s hospital can cut rates of patient ... care unit, a new study suggests. , "This is ... so that adds to the potential that having rapid ...
... Homecare Month, ARLINGTON, Va., Nov. 20 ... throughout the U.S. will celebrate,Thanksgiving and other holidays ... During November, which is National Homecare Month, the ... medical,equipment and therapies provided in the home offer ...
... and ... Flu Season, ... of,American Scientific Resources (Pink Sheets: ASFX), today announced the,launch of the ... available at Walgreens Stores,nationwide and online at http://www.kidzmed.com . ...
... Precision Optics,Corporation, Inc. (OTC Bulletin Board: POCI), (the "Company") ... first quarter of,fiscal year 2008 ended September 30, 2007. ... revenues for the quarter ended September 30, 2007,were $1,101,728, ... period in,the prior year. This represents the second highest ...
... Marketing Return: What can be measured? ... 2:30 p.m. GMT, WHERE: Pharmaceutical Marketing Society Half-day Conference, 20 Cavendish ... ... of the pharmaceutical analytics company Eularis, will be,delivering a presentation on marketing return ...
... and inexpensive diagnostic tool called MassTag PCR, scientists ... Center for Infection and Immunity implicated a new ... respiratory tract infections in Europe. Their findings are ... Journal of Infectious Diseases (currently available online). , ...
Cached Medicine News:Health News:Rapid Response Teams Can Save Hospitalized Kids 2Health News:Rapid Response Teams Can Save Hospitalized Kids 3Health News:Thanks to Homecare, Millions of Older Americans Celebrate Thanksgiving and Other Holidays at Home 2Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 2Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 3Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 2Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 3Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 4Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 5Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 6Health News:MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP? 2Health News:Recently discovered virus associated with pediatric respiratory tract infection in Germany 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: